Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause

Trial Profile

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs NT 814 (Primary)
  • Indications Vasomotor symptoms
  • Focus Therapeutic Use
  • Acronyms SWITCH-1
  • Sponsors KaNDy Therapeutics; NeRRe Therapeutics
  • Most Recent Events

    • 11 Dec 2018 According to a KaNDy Therapeutics media release, Prof. James A. Simon is the Coordinating Principal Investigator on the SWITCH-1 Study and Scientific and Clinical Advisor to KaNDy Therapeutics.
    • 11 Dec 2018 According to a KaNDy Therapeutics media release, the company announced the initiation of this study. The company is looking forward to reporting results in late 2019 and also it is expected that the drug will be fully phase III ready in the second half of 2020.
    • 11 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top